Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Abstract 6639: Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL

Praveen K. Bommareddy, Kevin Harrington, Victoria Roulstone, Joan Kyula, Aaron Clack, Linta Kuncheria, Sylwia Jones, Robert Coffin

Cancer Res (2023) 83 (7_Supplement): 6639.

https://doi.org/10.1158/1538-7445.AM2023-6639

Published: 04 April 2023

View article titled, Abstract 6639: Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL

Journal Articles

Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor

Jérôme Fayette, Tanguy Seiwert, Robert L. Ferris, Kevin Harrington, Robert Haddad, Makoto Tahara, Lisa Licitra, Lillian L. Siu, Jean-Pascal Machiels, Malgorzata Dominiewska, Julia Xiong, Paramjit Kaur, Dario Ruscica, Roger B. Cohen

Cancer Res (2022) 82 (12_Supplement): CT236.

https://doi.org/10.1158/1538-7445.AM2022-CT236

Published: 15 June 2022

View article titled, Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor

Journal Articles

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Kevin Harrington, Eileen Parkes, Jared Weiss, Mathew Ingham, Andrés Cervantes, Emiliano Calvo, Ute Klinkhardt, Patricia Sikken, Michael Schmohl, Elena Garralda

Cancer Res (2021) 81 (13_Supplement): CT217.

https://doi.org/10.1158/1538-7445.AM2021-CT217

Published: 01 July 2021

View article titled, Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Journal Articles

Abstract 1960: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors

Victoria Roulstone, Joan Kyula, Richard Elliot, Christopher J. Lord, Nik Matthews, Vicki Jennings, Harriet Whittock, David Mansfield, Jyoti Choudhary, James Wright, Lu Yu, Alan Melcher, Richard Vile, Matt Coffey, Martin McLaughlin, Kevin Harrington

Cancer Res (2021) 81 (13_Supplement): 1960.

https://doi.org/10.1158/1538-7445.AM2021-1960

Published: 01 July 2021

View article titled, Abstract 1960: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors

Journal Articles

Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy

Victoria Roulstone, Joan Kyula, Suzanne Thomas, Linta Kuncheria, Praveen K. Bommareddy, Henry Smith, Harriet Whittock, Robert S. Coffin, Kevin Harrington

Cancer Res (2021) 81 (13_Supplement): 1917.

https://doi.org/10.1158/1538-7445.AM2021-1917

Published: 01 July 2021

View article titled, Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy

Journal Articles

Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

James William Thomas Yates, Zena Wilson, Gemma N. Jones, Kevin Harrington, Matthew Krebs, Magnus Dillon, Andrew J. Pierce, Emma Dean, Alan Lau

Cancer Res (2020) 80 (16_Supplement): LB-104.

https://doi.org/10.1158/1538-7445.AM2020-LB-104

Published: 15 August 2020

View article titled, Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Journal Articles

Abstract CT244: A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Grace K. Dy, Diwakar Davar, Evanthia Galanis, Danielle Townsley, Djuro Karanovic, Maria Schwaederle, Beth Kelly, Dmitriy Zamarin, Mitesh Borad, Kevin Harrington

Cancer Res (2020) 80 (16_Supplement): CT244.

https://doi.org/10.1158/1538-7445.AM2020-CT244

Published: 15 August 2020

View article titled, Abstract CT244: A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Journal Articles

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Cancer Res (2020) 80 (16_Supplement): LB-258.

https://doi.org/10.1158/1538-7445.AM2020-LB-258

Published: 15 August 2020

View article titled, Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Journal Articles

Abstract 3415: Mutant BRAF small molecule inhibition enhances oncolytic herpes virus immunotherapy through increased immune cell recruitment and activation in melanoma

Galabina Bozhanova, Victoria Jennings, Malin Pedersen, Joan Kyula, Emmanuel Patin, Jehanne Hassan, Masahiro Ono, Kevin Harrington, Alan Melcher

Cancer Res (2020) 80 (16_Supplement): 3415.

https://doi.org/10.1158/1538-7445.AM2020-3415

Published: 15 August 2020

View article titled, Abstract 3415: Mutant BRAF small molecule inhibition enhances oncolytic herpes virus immunotherapy through increased immune cell recruitment and activation in melanoma

Journal Articles

Abstract 3987: Direct cancer cell/cancer-associated fibroblast interaction elicits resistance to oncolytic virus therapy in squamous cell carcinoma

Antonio Rullan, Emma Milford, Esther Arwert, Alan Melcher, Kevin Harrington, Erik Sahai

Cancer Res (2020) 80 (16_Supplement): 3987.

https://doi.org/10.1158/1538-7445.AM2020-3987

Published: 15 August 2020

View article titled, Abstract 3987: Direct cancer cell/cancer-associated fibroblast interaction elicits resistance to oncolytic virus therapy in squamous cell carcinoma

Journal Articles

Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

Alienor Berges, S. Y. Amy Cheung, Andrew J. Pierce, Emma Dean, Brunella Felicetti, Nathan Standifer, Simon Smith, James Yates, Alan Lau, Christine Stephens, Matthew Krebs, Kevin Harrington, Simon J. Hollingsworth

Cancer Res (2018) 78 (13_Supplement): CT118.

https://doi.org/10.1158/1538-7445.AM2018-CT118

Published: 01 July 2018

View article titled, Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

Journal Articles

Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141

Robert L. Ferris, George Blumenschein, Kevin Harrington, Jérôme Fayette, Joël Guigay, A. Dimitrios Colevas, Lisa Licitra, Everett Vokes, Maura Gillison, Caroline Even, Cheryl Ho, Makoto Tahara, Robert Haddad, Mark Lynch, Manish Monga, Somnath Bandyopadhyay, Omar Jabado, Henry Kao

Cancer Res (2017) 77 (13_Supplement): CT022.

https://doi.org/10.1158/1538-7445.AM2017-CT022

Published: 01 July 2017

View article titled, Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141

Journal Articles

Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141

Cancer Res (2017) 77 (13_Supplement): CT021.

https://doi.org/10.1158/1538-7445.AM2017-CT021

Published: 01 July 2017

View article titled, Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141

Journal Articles

Abstract CT115: Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

Hardev Pandha, Kevin Harrington, Cristy Ralph, Alan Melcher, Sumati Gupta, Wallace Akerley, Rachael E. Sandborn, Charles Rudin, Jonathan Rosenberg, David Kaufman, Emmett Schmidt, Mark Grose, Darren R. Shafren

Cancer Res (2017) 77 (13_Supplement): CT115.

https://doi.org/10.1158/1538-7445.AM2017-CT115

Published: 01 July 2017

View article titled, Abstract CT115: Phase 1b <em>KEYNOTE 200 (STORM study):</em> A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

Journal Articles

Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study

Robert Haddad, Robert L. Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, Alexander D. Colevas, Lisa Licitra, Stefan Kasper, Everett E. Vokes, Francis Worden, Nabil F. Saba, Makoto Tahara, Manish Monga, Mark Lynch, Jin Zhu, James W. Shaw, Maura L. Gillison, Kevin Harrington

Cancer Res (2017) 77 (13_Supplement): CT157.

https://doi.org/10.1158/1538-7445.AM2017-CT157

Published: 01 July 2017

View article titled, Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study

Journal Articles

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

Cancer Res (2016) 76 (14_Supplement): CT099.

https://doi.org/10.1158/1538-7445.AM2016-CT099

Published: 15 July 2016

View article titled, Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

Journal Articles

Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses

Karishma Rajani, Christopher Parrish, Kevin Shim, Liz Ilett, Fiona Errington-Mais, Jill Thompson, Tim Kottke, Rosa Maria-Diaz, Peter Selby, Hardev Pandha, Kevin Harrington, Alan Melcher, Matt Coffey, Shane Zaidi, Richard Vile

Cancer Res (2015) 75 (15_Supplement): 1360.

https://doi.org/10.1158/1538-7445.AM2015-1360

Published: 01 August 2015

View article titled, Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses

Journal Articles

Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients

Hardev Pandha, Kevin Harrington, Cristy Ralph, Alan Melcher, Darren R. Shafren

Cancer Res (2015) 75 (15_Supplement): CT205.

https://doi.org/10.1158/1538-7445.AM2015-CT205

Published: 01 August 2015

View article titled, Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients

Journal Articles

Abstract 3100: HOX transcription factors promote cell survival in breast cancer

Richard Morgan, Agnieszka Michael, Aagna Bhatt, Kevin Harrington, Angela Boxall, Nicola Annels, Hardev Pandha

Cancer Res (2011) 71 (8_Supplement): 3100.

https://doi.org/10.1158/1538-7445.AM2011-3100

Published: 15 April 2011

View article titled, Abstract 3100: HOX transcription factors promote cell survival in breast cancer

Journal Articles

Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70–Mediated Inflammatory Killing of Normal Pancreas

Timothy Kottke, Jose Pulido, Jill Thompson, Luis Sanchez-Perez, Heung Chong, Stuart K. Calderwood, Peter Selby, Kevin Harrington, Scott E. Strome, Alan Melcher, Richard G. Vile

Cancer Res (2009) 69 (19): 7767–7774.

https://doi.org/10.1158/0008-5472.CAN-09-1597

Published: 01 October 2009

View article titled, Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70–Mediated Inflammatory Killing of Normal Pancreas

NARROW

Abstract 6639: Preclinical characterization and clinical biomarker studies with RP3, a novel oncolytic immunotherapy expressing a fusogenic protein, a human anti-CTLA-4 antibody, hCD40L and h4-1BBL

Abstract CT236: INTERLINK-1: A phase 3, randomized, double-blind, placebo-controlled, multicenter, global study of monalizumab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma previously treated with an immune checkpoint inhibitor

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Abstract 1960: Mechanisms of therapeutic synergy between pattern recognition response agonists and cdk4 inhibitors

Abstract 1917: Immunomodulatory effects of a novel, enhanced potency gibbon ape leukaemia virus (GALV) fusogenic membrane glycoprotein-expressing herpes simplex virus platform with increased efficacy combined with anti PD-1 therapy

Abstract LB-104: Quantification of the preclinical and clinical relationship between pRAD50 and efficacy after treatment with the ATR inhibitor ceralasertib (AZD6738)

Abstract CT244: A phase 1 study of IV MEDI5395, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors

Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Abstract 3415: Mutant BRAF small molecule inhibition enhances oncolytic herpes virus immunotherapy through increased immune cell recruitment and activation in melanoma

Abstract 3987: Direct cancer cell/cancer-associated fibroblast interaction elicits resistance to oncolytic virus therapy in squamous cell carcinoma

Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor)

Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141

Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141

Abstract CT115: Phase 1b KEYNOTE 200 (STORM study): A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients

Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

Abstract 1360: Combination therapy of reovirus and PD-1 blockade effectively establishes tumor control via innate and adaptive immune responses

Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients

Abstract 3100: HOX transcription factors promote cell survival in breast cancer

Antitumor Immunity Can Be Uncoupled from Autoimmunity following Heat Shock Protein 70–Mediated Inflammatory Killing of Normal Pancreas

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only